NGS Banner
Contributors

Graham Speight1 , Ephrem Chin1 , Lyudmila Georgieva1, Nick Cross2 and David Cook1

1OGT, Oxford, UK and 2 National Genetics Reference Laboratory - Wessex, UK

 

Introduction

  • Myeloproliferative neoplasms (MPNs) are a group of diseases that affect blood cell production in the bone marrow resulting in the overproduction of one or more cell types. The key MPN driver mutations involve JAK2 (V617F [occurrence of 50-98% depending on the MPN subtype]), JAK2 exon 12, MPL W515K/L and CALR exon 9 insertion and deletions. 
  • Designed for research into the diagnosis, aetiology and prognosis of MPNs, the SureSeq™ Core MPN Panel has been developed by OGT in collaboration with recognised cancer experts to deliver accurate detection (down to a 1% variant allele fraction [VAF]) of somatic variants of these key MPN driver mutations. 
  • The aim of this study is to evaluate the SureSeq Core MPN Panel in conjunction with a new streamlined 1-day hybridisation-based Next Generation Sequencing (NGS) library preparation kit (LPK).

Register with us to read the full article

Once you have registered with us for free you will be able to read all our supportive literature, video tutorials and webinars.

Related content

  • Share
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter